Physician profile
Robert P Chen
NPI 1255335816
$1,212.21
in general payments reported to CMS, 2019-2025
28 companies · $80.25 in 2025
The $80.25 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $184 · 2021: $86.57 · 2022: $63.45 · 2023: $6.93 · 2024: $68.43 · 2025: $80.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $143.36 | 2019-2025 | |
| Novo Nordisk INC | $117.93 | 2019-2021 | |
| Astellas Pharma US INC | $109.12 | 2019-2020 | |
| Pacira Therapeutics, INC. | $99.03 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $86.53 | 2019-2024 | Breztri |
| Pfizer INC. | $86.02 | 2019-2020 | |
| Allergan, INC. | $84.57 | 2019 | |
| Exact Sciences Corporation | $42.79 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $40.84 | 2020 | |
| Amarin Pharma, INC. | $39.74 | 2019-2020 | |
| Inspire Medical Systems, INC. | $37.37 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $35.56 | 2019 | |
| Amgen INC. | $31.44 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $28.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.08 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.87 | 2019 | |
| Edwards Lifesciences Corporation | $21.49 | 2022 | |
| Tonix Medicines, INC. | $19.06 | 2025 | Tonmya |
| Merck Sharp & Dohme LLC | $18.39 | 2022 | |
| Sanofi Pasteur INC. | $14.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.65 | 2019 | |
| Glaxosmithkline, LLC. | $14.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.00 | 2019 | |
| Lilly USA, LLC | $11.46 | 2019 | |
| Medtronic, INC. | $11.21 | 2021 | |
| Organon LLC | $6.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.